Roivant Sciences | search
Click here to view Roivant Sciences news from 60+ newspapers.
Bookmark or Share- Thompson Siegel & Walmsley LLC Takes $5.93 Million Position in Roivant ...Roivant Sciences Ltd. has a 12-month low of $8.61 and a 12-month high of $13.06. Analyst Ratings Changes. ROIV has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Bank of America raised their price objective on ...
- Roivant Sciences - WikipediaRoivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. [3]
- RoivantRoivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.
- Our Companies | Roivant - Roivant SciencesView our broad and differentiated pipeline of investigational drugs. Join the team changing the future of healthcare. A career at Roivant is filled with remarkable growth opportunities for those tackling the most significant challenges in science and technology.
- Investor Relations | Roivant Sciences Ltd.Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies.
More
